KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Minimal incision-assisted endoscopic versus conventional open breast-conserving surgery: A multicentre randomized clinical trial.

Mengxue Qiu, Hui Dai, Tao Zhu, Faqing Liang, Yu Feng, Yanyan Xie, Hao Wu, Guilin Luo, Zhengyi Liu, Donglin Zhang, Yang Yu, Zhenggui Du

Breast 89 104876

PMID42497645
PMCID-
DOI10.1016/j.breast.2026.104876
发表日期2026-07-24
入排依据:The record meets criteria for oncology, human, randomized, Phase III, and original result. However, it is excluded because the intervention is non-drug (surgical procedure comparison) and the primary endpoint is not a time-to-event efficacy outcome. The study lacks a drug intervention and a time-to-event endpoint, which are mandatory for eligibility.
摘要

摘要

BACKGROUND: Compared with conventional open breast-conserving surgery (BCS), conventional endoscopic (E-BCS) mostly involves dual incisions, which provide an insignificant scarring benefit but increase the surgical difficulty and prolong the surgical time. In contrast, the novel minimal incision-assisted E-BCS (M-E-BCS) procedure enables a near-scarless operation with efficient and precise tumour resection through a single axillary incision. METHODS: This is a phase III, open-label, multicentre, superiority, randomized controlled trial conducted in 3 class IIIA hospitals in China. Patients were assigned to M-E-BCS or conventional open BCS (C-O-BCS). The aim was to compare aesthetic outcomes, surgical efficiency, and safety. The primary endpoint was the patient-reported SCAR-Q score for scar appearance satisfaction at 18 months postoperatively. Secondary endpoints included aesthetic outcomes, quality of life (QoL), operative time, complications, and oncologic outcomes. RESULTS: Overall, 163 patients were analysed, with 82 in the M-E-BCS group and 81 in the C-O-BCS group. The 18-month SCAR-Q score was available for 155 patients (8 missing, 4 per group). M-E-BCS demonstrated superior SCAR-Q scores (79.9 ± 9.5 vs. 61.4 ± 17.4, P < 0.001), greater improvement in BREAST-Q breast satisfaction (17.7 ± 18.2 vs. 5.4 ± 21.5, P < 0.001), and better psychosocial well-being (10.1 ± 19.2 vs. 0.1 ± 19.3, P = 0.001) at 18 months. The physician assessment (Ueda score) showed a higher "excellent" rate for M-E-BCS (86.5% vs. 57.9%). Operative time (130.8 ± 37.9 vs. 121.8 ± 30.5 min, P = 0.167), complication rates (11.0% vs. 13.6%, P = 0.612), and short-term oncologic outcomes were not significantly different between groups. The median follow-up was 30.0 months (range 19.0-45.0 months). One patient in the C-O-BCS group developed bone metastasis at 5 months, and another developed axillary lymph node recurrence at 17 months. No local recurrence or death occurred in either group. CONCLUSION: M-E-BCS significantly improves aesthetic outcomes and QoL compared to C-O-BCS, without compromising surgical efficiency or safety for early-stage breast cancer patients, supporting its clinical adoption. TRIAL REGISTRATION: ChiCTR2200061907.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。